Literature DB >> 32015994

Can immune biomarkers predict benefit from targeted agents in metastatic renal cell carcinoma?

Renate Pichler1, Manuela Schmidinger2.   

Abstract

Entities:  

Year:  2019        PMID: 32015994      PMCID: PMC6976423          DOI: 10.21037/atm.2019.11.138

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  18 in total

Review 1.  The future of immune checkpoint therapy.

Authors:  Padmanee Sharma; James P Allison
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

2.  Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

Authors:  Toni K Choueiri; Susan Halabi; Ben L Sanford; Olwen Hahn; M Dror Michaelson; Meghara K Walsh; Darren R Feldman; Thomas Olencki; Joel Picus; Eric J Small; Shaker Dakhil; Daniel J George; Michael J Morris
Journal:  J Clin Oncol       Date:  2016-11-14       Impact factor: 44.544

3.  Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

Authors:  Toni K Choueiri; Bernard Escudier; Thomas Powles; Nizar M Tannir; Paul N Mainwaring; Brian I Rini; Hans J Hammers; Frede Donskov; Bruce J Roth; Katriina Peltola; Jae Lyun Lee; Daniel Y C Heng; Manuela Schmidinger; Neeraj Agarwal; Cora N Sternberg; David F McDermott; Dana T Aftab; Colin Hessel; Christian Scheffold; Gisela Schwab; Thomas E Hutson; Sumanta Pal; Robert J Motzer
Journal:  Lancet Oncol       Date:  2016-06-05       Impact factor: 41.316

4.  Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.

Authors:  Robert J Motzer; Dmitry Nosov; Timothy Eisen; Igor Bondarenko; Vladimir Lesovoy; Oleg Lipatov; Piotr Tomczak; Oleksiy Lyulko; Anna Alyasova; Mihai Harza; Mikhail Kogan; Boris Y Alekseev; Cora N Sternberg; Cezary Szczylik; David Cella; Cristina Ivanescu; Andrew Krivoshik; Andrew Strahs; Brooke Esteves; Anna Berkenblit; Thomas E Hutson
Journal:  J Clin Oncol       Date:  2013-09-09       Impact factor: 44.544

5.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Brian I Rini; Elizabeth R Plimack; Viktor Stus; Rustem Gafanov; Robert Hawkins; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Anna Kryzhanivska; Igor Bondarenko; Sergio J Azevedo; Delphine Borchiellini; Cezary Szczylik; Maurice Markus; Raymond S McDermott; Jens Bedke; Sophie Tartas; Yen-Hwa Chang; Satoshi Tamada; Qiong Shou; Rodolfo F Perini; Mei Chen; Michael B Atkins; Thomas Powles
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

Review 6.  Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.

Authors:  Aly-Khan A Lalani; Bradley A McGregor; Laurence Albiges; Toni K Choueiri; Robert Motzer; Thomas Powles; Christopher Wood; Axel Bex
Journal:  Eur Urol       Date:  2018-10-13       Impact factor: 20.096

7.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

8.  Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.

Authors:  Xian-De Liu; Anh Hoang; Lijun Zhou; Sarathi Kalra; Alper Yetil; Mianen Sun; Zhiyong Ding; Xuesong Zhang; Shanshan Bai; Peter German; Pheroze Tamboli; Priya Rao; Jose A Karam; Christopher Wood; Surena Matin; Amado Zurita; Axel Bex; Arjan W Griffioen; Jianjun Gao; Padmanee Sharma; Nizar Tannir; Kanishka Sircar; Eric Jonasch
Journal:  Cancer Immunol Res       Date:  2015-05-26       Impact factor: 11.151

9.  PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.

Authors:  Toni K Choueiri; Sabina Signoretti; Abdallah Flaifel; Wanling Xie; David A Braun; Miriam Ficial; Ziad Bakouny; Amin H Nassar; Rebecca B Jennings; Bernard Escudier; Daniel J George; Robert J Motzer; Michael J Morris; Thomas Powles; Evelyn Wang; Ying Huang; Gordon J Freeman
Journal:  Clin Cancer Res       Date:  2019-08-01       Impact factor: 12.531

10.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.